Beam Therapeutics (BEAM) Projected to Post Earnings on Tuesday

Key Points

• Beam Therapeutics (NASDAQ:BEAM) is set to announce its Q2 2025 earnings on August 5th, with analysts expecting a loss of ($1.04) per share and revenue of $13.29 million.
• In its previous earnings report on May 6th, the company reported a loss of ($1.24) per share and a revenue of $7.47 million, missing expectations.
• Institutional investors, including Jones Financial Companies, have significantly increased their positions in Beam, now holding 99.68% of the stock.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of ($1.04) per share and revenue of $13.29 million for the quarter.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.13). The business had revenue of $7.47 million during the quarter, compared to analysts' expectations of $14.69 million. Beam Therapeutics had a negative return on equity of 44.24% and a negative net margin of 609.24%. The company's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.21) EPS. On average, analysts expect Beam Therapeutics to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Beam Therapeutics Price Performance

Shares of NASDAQ BEAM traded down $0.90 during trading on Tuesday, hitting $19.93. 1,894,480 shares of the company were exchanged, compared to its average volume of 2,368,679. Beam Therapeutics has a 1 year low of $13.52 and a 1 year high of $35.25. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -4.32 and a beta of 2.07. The firm's fifty day moving average price is $18.47 and its 200 day moving average price is $21.29.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on BEAM shares. Cantor Fitzgerald upgraded shares of Beam Therapeutics to a "strong-buy" rating in a research report on Monday, July 21st. Guggenheim decreased their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research note on Monday, April 7th. Barclays cut their target price on shares of Beam Therapeutics from $31.00 to $25.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Finally, Wells Fargo & Company lowered their price target on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, ten have given a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $48.75.

Institutional Investors Weigh In On Beam Therapeutics

An institutional investor recently raised its position in Beam Therapeutics stock. Jones Financial Companies Lllp boosted its holdings in Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) by 55,780.0% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 33,528 shares of the company's stock after buying an additional 33,468 shares during the period. Jones Financial Companies Lllp's holdings in Beam Therapeutics were worth $655,000 at the end of the most recent reporting period. 99.68% of the stock is currently owned by hedge funds and other institutional investors.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.